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Objective. To prospectively evaluate if computed tomography perfusion (CTp) could be a useful tool in addition to multiphasic
CT in renal lesion characterisation. Materials and Methods. Fifty-eight patients that were scheduled for surgical resection of a
renal mass with a suspicion of renal cell carcinoma (RCC) were enrolled. Forty-one out of 58 patients underwent total or partial
nephrectomy after CTp examination, and a pathological analysis was obtained for a total of 49 renal lesions. Perfusion parameters
and attenuation values at multiphasic CT for both lesion and normal cortex were analysed. All the results were compared with the
histological data obtained following surgery. Results. PS and MTT values were significantly lower in malignant lesions than in the
normal cortex (𝑃 < 0.001 and 𝑃 = 0.011, resp.); PS, MTT, and BF values were also statistically different between oncocytomas
and malignant lesions. According to ROC analysis, the accuracy, sensitivity, and specificity to predict RCC were 95.92%, 100%, and
66.7%, respectively, for CTp whereas they were 89.80%, 93.35%, and 50%, respectively, for multiphasic CT.Conclusion.A significant
difference between renal cortex and tumour CTp parameter values may suggest a malignant renal lesion. CTp could represent an
added value to multiphasic CT in differentiating renal cells carcinoma from oncocytoma.
1. Introduction
Renal cell carcinoma (RCC) represents 3-4% of all malignan-
ciesworldwide [1]. It is classified into several typeswhich have
different features and clinical behaviours; however histologic
type is one of the most important prognostic factors. Clear
cell RCC, the most common type, accounting for 65–70%,
has a high metastatic potential, whereas papillary RCC (10–
15% of RCCs) and chromophobe RCC (5% of RCCs) have a
low metastatic potential. The other malignant RCCs account
for 5 to 6%. Approximately 20% of renal lesions are benign,
and oncocytoma, which accounts for 5% of all renal tumours,
is the most common type [2, 3]. RCC’s incidence has risen
over the last few years because the widespread use of cross-
sectional imaging has increased the incidental detection of
renal lesions, particularly those of a small size (<4 cm) [4, 5].
Although the great value of imaging for renal lesions detec-
tion has increased in recent years, the accuracy rate on
preoperative characterisation of their nature remains low [6];
in particular the differential diagnosis of oncocytoma versus
RCC represents a diagnostic challenge [7]. Percutaneous
biopsy could be a useful tool in dubious cases, but it is an
invasive approach [8, 9]. Recently, computed tomography
perfusion (CTp), a functional tool which allows a quantitative
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evaluation of tissue perfusion through consecutive scans
acquired during contrast media injection, showed promising
results in the oncologic field, even in renal lesion characteri-
sation [10]. It is based on a time-density curve developed by
software, but its reliability is still being evaluated. Further-
more the parameters used are not standardised yet, because
of the availability of different software platforms and the
different version upgrades of the same software, which show
different perfusion measurements [11]. The identification of
renal lesion type, firstly discriminating between malignant
and benign, could represent an important diagnostic goal in
order to choose the best management: diagnosis of RCC at
an early stage means a less invasive therapeutic approach and
a better prognosis, while identifying a benign lesion could
avoid any unnecessary surgical intervention. By examining
the previous consideration, the aim of our study was to
prospectively evaluate if CTp could be a useful tool in
addition to multiphasic CT in renal lesion characterisation.
2. Materials and Methods
2.1. Study Population. Our study had institutional review
board approval and a written informed consent was obtained
from all patients. Fifty-eight patients scheduled for surgical
resection of a renal mass with a suspicion of RCC between
April 2012 and December 2013 were considered for the study
enrollment. All of these patients underwent renal CTp imag-
ing and staging thoracic and abdominal CT scans. Seventeen
patients were excluded as their CTp studies were not evalu-
able due to significant respiratory artifacts (𝑛 = 8), or the sur-
gical procedure was performed in another hospital (𝑛 = 9).
Among 58 patients included in this study, 41 (26 males, mean
age of 60.76 years, range 39–86 years) underwent total or
partial surgical nephrectomy at our hospital within 15.3 days
(range: 1–25 days) after CTp examination, and a pathological
analysis was obtained for a total of 49 renal lesions.
2.2. CT Examination. All patients were examined using a 64-
detector row CT scanner (Discovery 750 HD, GEHealthcare,
Milwaukee, WI, USA). To reduce respiratory artifacts, a belt
over the abdomen was used and patients were instructed to
breathe gently during the scan acquisition. An unenhanced
CT scan of the upper abdomen covering the kidneys was
performed initially to locate the renal lesion. A supervising
radiologist (9 years of experience in CTp) identified the
tumour and then placed the predefined scan volume (80mm
for shuttle axial technique and 40mm for cine technique)
in the 𝑧-axis to cover the lesion for the CTp study. Cine
technique was used when the lesion was smaller than 20mm.
For the CTp study, 100mL of Iomeprol (Iomeron 400;
Bracco,Milan, Italy) was administered intravenously at a flow
rate of 5mL/s followed by 40mL of saline solution at the
same flow rate. The dynamic cine acquisition consisted of 8
contiguous sections, collimated to 5mm, with temporal res-
olution of 1 second by using a cine-mode acquisition without
table movement and with the following parameters: 100Kv,
80mAs, rotation time 0.5 s, and scan field of view of 50 cm,
whereas it consisted of 8 contiguous sections, collimated to
5mm, with temporal resolution of 2.8 seconds by using a
shuttle-mode acquisition with table movement (21 passes)
and with the following parameters: 100Kv, 80mAs, rotation
time 0.4 s, and scan field of view of 50 cm. Total duration
time was approximately 60 seconds in order to include
both first-pass enhancement and delayed phase. Scanning
commenced 6 seconds after the start of the contrast material
injection in order to ensure the acquisition of a little nonen-
hanced baseline data both to allow the software to plot the
enhancement change over time and to allow the radiologists
to evaluate the lesion’s density upon unenhanced CT at
the multiphasic CT density evaluation. Immediately after
completion of the CTp scans, a conventional diagnostic CT
of the abdomen and thorax (CT nephrographic phase, delay
of 60 to 80 s, slice thickness 2.5mm, reconstruction interval
1mm, collimation 40mm, beam pitch 0.98, 140 kV, and 200–
700mA with automatic scan exposure) was performed with
the intravenous administration of an additional amount of
the same nonionic iodinated contrast medium mentioned
previously at a rate of 4mL/sec (up to a total amount of about
150–160mL of iodinated contrast medium according to the
patient body weight), followed by a 20mL bolus of saline
solution administered at the same rate. Finally an excretory
phase CT urography was obtained after 5 to 10 minutes of
the contrast media injection for 32 out of the 41 patients. All
the CT scans were performed by using the adaptive statistical
iterative reconstruction (ASIR, 30%) system in order to
reduce the dose exposure to the patient.
2.3. Image Analysis. Image analysis was performed in con-
sensus by a radiologist and a resident fellow in radiology
(with 9 and 2 years of experience in CTp, resp.). All CTp
studies were analysed by using a commercial perfusion
software (Body Tumor CT Perfusion Software version 3; GE
Healthcare). For the CTp analysis, a processing threshold
(CT value range) between 0 and 120 Hounsfield units (HU)
was utilised to optimise visualisation of the soft tissue.
On transverse CT images, the slice showing the maximal
transverse tumour diameter was chosen for further analysis.
The arterial input was determined by placement of a circular
region of interest (ROI) in the abdominal aorta, to measure
the arterial input function. An arterial time-density curve
(TDC) for the entire acquisition time of each study was gen-
erated automatically. In the same selected image, ROIs of the
renal tumour and normal renal cortex were drawn manually
(maximum 1 cm2), lying within the structure of interest in
each slice and excluding necrosis, calcifications, or cystic or
any hemorrhagic areas. Mean values for four CTp parameters
(permeability surface, PS; mean transit time, MTT; blood
volume, BV; and blood flow, BF) were obtained and recorded
for each patient. For the multiphasic evaluation, both the
baseline noncontrast phase and the corticomedullary phase
(CM) were evaluated on the CTp images: in particular CM
phase imaging occurred 35 seconds after the threshold level
of 150 HU was reached in the ROI placed in the aorta.
The nephrographic phase (NG) imaging occurred 60 to 80
seconds after the threshold level of 150 HU was reached
and the excretory phase imaging occurred 5 to 10 minutes
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after the threshold level of 150 HU was reached. On the
basis of the normal appearance of renal parenchyma, images
from these protocols were classified as unenhanced if there
was no contrast material administration, corticomedullary
if the renal cortex but not the medulla enhanced in a
ribbon-like pattern, nephrographic if the cortex and medulla
enhanced uniformly, or excretory if the concentrated contrast
material was excreted in the renal pelvis and ureters after
the prior phases. Average tumour attenuation measurements
were determined in each phase; average cortical and aorta
attenuation measurements were taken in the same image
in which the tumour attenuation was determined. Absolute
enhancement was defined as the difference in mean HU
between the noncontrast phase and any given contrast
phase (CM, NG, or excretory); percentage enhancement was
calculated as the mean HU in the tumour divided by
the mean HU of the tumour in the noncontrast phase.
Relative enhancement to renal cortex (or cortical-tumour
relative enhancement) was defined as the difference between
mean tumour enhancement and renal cortical enhance-
ment during a given phase, whereas the cortical-tumour
ratio was defined as mean tumour enhancement divided
by renal cortical enhancement during any given phase; rela-
tive enhancement to aorta (or aorta-tumour relative enhance-
ment) was also calculated as the difference between mean
tumour enhancement and aorta enhancement during a given
phase, whereas the aorta-tumour ratio was defined as mean
tumour enhancement divided by aorta enhancement during
any given phase. For each patient, aorta, cortical, and lesion
ROIs were fixed in the same location and in the same axial
slice level to subsequently enable an identical placement at
the same lesion axial slice level for the multiphasic analysis
by saving the ROIs within the software platform. The ROIs
were reviewed by each reader for appropriate placement.
The maximal diameter of each lesion was measured on axial
images, and this measurement was reviewed by each reader;
renal lesions were defined “hypervascular” if enhancement in
the nephrographic phase was greater than or equal to that of
renal cortex (in HU density) [12].
2.4. Histopathology. The surgical specimen consisted of rad-
ical nephrectomy in 31 out of 41 (75%) patients and partial
nephrectomy in 10 out of 41 (25%) patients. In addition to
routine samples for pathologic diagnosis, additional tissue
blocks from each tumour as well as from normal renal
tissue were acquired for additional histological examination
and immunohistochemical staining by the pathologist. The
pathologist took care to ensure sampling at a tumour level
corresponding to the level at which CTp was performed.
In particular on CT images the distance between the CT
slice showing the maximal transverse tumour diameter and
the lower or upper pole of the kidney or, in case of partial
nephrectomy, the lower or upper margin of the tumour
was measured. One pathologist and one radiologist (who
supervised the CTp study) jointly performed the processing
of all surgical specimens and reported the coordinates of
the slice analysed on CTp images. All tissue specimens were
fixed in a 10% buffered formalin and embedded in paraffin.
The surgical specimens were sliced in the transverse plane
at the level of the maximal tumour diameter, according
to the distance measured on CT images. The macroscopic
appearance of the transversally sliced surgical specimen was
compared with the appearance of the corresponding tumour
plane on transverse CT images to ensure that they were
similar. From each block, 4-micron-thick sections were cut.
The sections were stained with hematoxylin and eosin. All
tumours were staged based on the last TNM classification
system (TNM7) and the 4-tiered Fuhrman grading system
was used to grade the tumours (MTdV). Quantification of
microvessel density (MVD) was performed after immunos-
taining with a CD34 monoclonal antibody (clone QBEnd/10,
ready to use) by light microscopy using the counting method
introduced by Weidner et al. [13, 14] and stained with CD34
for quantification of MVD. The staining was performed on
a Bond Max automated immunostainer (Leica Microsystem,
Bannockburn, IL, USA) by a monoclonal antibody (predilute
AP 125; ProgenBiotechnik GmbH, Maabstrasse, Heidelberg,
Germany) with controls in parallel. No epitope retrieval
was used. Ultravision Detection System using antipolyvalent
HRP (LabVision, Fremont, CA, USA) and diaminobenzidine
(DAB, Dako, Milan, Italy) as chromogen was used. Briefly,
the whole slide was viewed at ×100 magnification and the
area containing the maximum number of microvessels (the
“hotspot” area) was identified. The precise topography of
the angiogenic hotspots in carcinomas was assessed by
measuring their distance from the tumour edge; hotspots
within 0.5mm were considered marginal. Then, under x400
magnification (where one field is equivalent to 0.19mm2)
individual microvessels were counted. The number of vessels
in six areas was counted and averaged as MVD. Both isolated
immunoreactive endothelial cells and luminal microvascu-
lar structures were considered countable vessels. Distinct
endothelial cell staining of the renal vasculature served as
a positive control. Occasional immunoreactive macrophages
and plasma cells were excluded, based on theirmorphological
appearance. Assessment of MVD was completed without
knowledge of any clinicopathological data and blinded to the
results from CT perfusion imaging. Two pathologists (MRA
and BJR) counted MVD, respectively, and mean values were
calculated and recorded for each patient. Disagreements on
what constituted a microvessel were resolved by consensus.
2.5. Statistical Analysis. Shapiro Wilk test was used to test
the normality of variables. CTp parameters in tumour tissue
and adjacent normal parenchyma were compared using
Wilcoxon signed-rank test; differences in CTp parameters
and multiphasic CT measurements between benign and
malign tumours and between benign and malign hypervas-
cular tumours were assessed by using the Wilcoxon-Mann-
Whitney test; Kruskal-Wallis test was used to compare CTp
parameters between the three malignant histologic subtypes;
a 𝑃 value less than 0.05 indicated a statistically significant
difference. Spearman test was used to evaluate the correla-
tion between MVD and selected CTp and multiphasic CT
measurements. For this analysis, the Bonferroni correction
was used and the significance level was set to 0.0071. Diag-
nostic accuracy of variables was measured by using receiver
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(a) (b)
(c) (d)
Figure 1: CTp of clear cell RCC: ROI 1, ROI 2, and ROI 3 were drawn in the aorta, tumour, and healthy ipsilateral renal cortex, respectively
(a-b). The PS values of the tumour and normal cortex were 42.90mL/100 g/min and 67.64mL/100 g/min, respectively, whereas MTT values
were 13.73 sec and 3.59 sec, respectively (b). Lesion size was 20mm. Histopathology: morphology, haematoxylin, and eosin (c) and CD34
stain (d); original magnification: 50x.
operating characteristic (ROC) analysis. ROC curves were
analysed to determine the cutoffs that maximise the number
of correctly classified lesions. All analyses were carried out
using STATA statistical software V.12.1 (StataCorp, Texas).
3. Results
All patients underwent CTp imaging without any adverse
effects. Three out of 41 patients had multiple lesions; more
specifically, of the 3 patients who had multiple lesions, 1 had
six lesions, 1 had three lesions, and 1 had two lesions, for a
total of 49 renal lesions. Of the 49 renal lesions included in
this study, 27 (55%) were clear cell RCCs, 10 (21%) were chro-
mophobe RCCs, 6 (12%) were papillary RCCs, and 6 (12%)
were oncocytomas. Mean lesion diameters were 51.25mm for
clear cell RCCs, 44.2mm for chromophobe RCCs, 26.6mm
for papillary RCCs, and 48.5mm for oncocytomas. The
pathologic tumour stage and baseline characteristics for each
of the groups are presented in Table 1. Forty out of 49 lesions
(82%) had been imaged also with an excretory CT scan after
the CTp study (32 out of 41 patients). 25 out of 49 lesions
(51%) were hypervascular at CT examination (17 clear cell
RCCs, 2 chromophobe RCCs, 2 papillary RCCs, and 4 onco-
cytomas), 14 out of 49 lesions (29%) were hypervascular with
a necrotic core (10 clear cell RCCs, 2 chromophobe RCCs,
and 2 oncocytomas), and 10 (20%) were hypovascular (6
chromophobe RCCs and 4 papillary RCCs).
3.1. CTp Measurements. Mean perfusion CT parameter val-
ues (PS, MTT, BV, and BF) for the normal renal cortex and
renal tumours (oncocytomas andmalignant lesions) are sum-
marised in Table 2. There were significant differences in PS
(𝑃 < 0.001) and MTT (𝑃 = 0.011) between tumour and nor-
mal renal cortex in malignant lesions (clear cell carcinoma,
chromophobe carcinoma, and papillary carcinoma) whereas
there were no differences in any CTp parameters between
lesion and normal renal cortex in oncocytomas (Figures 1
and 2). There were also significant differences in PS, MTT,
and BF parameters between oncocytomas and all malignant
renal lesions and in PS and MTT between oncocytomas and
malignant hypervascular lesions, with or without necrosis
(Table 3). Significant differences were also found in PS (𝑃 =
0.0137), BV (𝑃 = 0.0106), BF (𝑃 = 0.0258), and MTT
(𝑃 = 0.0084) among the three different pathologic types of
malignant lesions. The CTp parameter with the highest
capacity for discriminating benign from malignant lesions,
evaluated throughROCanalysis, was PS (maximumaccuracy
BioMed Research International 5
Table 1: Characteristics of patients, renal lesions, and CT examination.
Characteristics All lesions(% or range)
Clear cell RCC
(% or range)
Chromophobe RCC
(% or range)
Papillary RCC
(% or range)
Oncocytoma
(% or range)
𝑁patients 41 26∗ 5 5∗ 6
Sex
Male 26 (63) 16 (62) 3 (60) 5 (100) 3 (50)
Female 15 (37) 10 (38) 2 (40) 0 3 (50)
Mean age 60.76 (39–86) 65.29 (39–86) 53.4 (39–60) 58.16 (42–63) 64.5 (44–80)
𝑁 lesions 49 27 (55) 10 (21) 6 (12) 6 (12)
Side
Right 25 (51) 14 (52) 6 (60) 3 (50) 2 (33)
Left 24 (49) 13 (48) 4 (40) 3 (50) 4 (67)
Location
UP 10 (20) 6 (22) 2 (20) 2 (33) 0
UP-MR 5 (10) 3 (11) 1 (10) 0 1 (17)
MR 15 (31) 7 (26) 4 (40) 3 (50) 1 (17)
LP-MR 7 (14) 6 (22) 0 0 1 (17)
LP 12 (25) 5 (19) 3 (30) 1 (17) 3 (49)
Mean lesion diameter (mm) 45.62 (10–128) 51.25 (20–128) 44.2 (10–110) 26.66 (17–40) 48.5 (20–116)
Pathologic tumour stage
T1a 20 (46) 9 (33) 5 (50) 6 (100) —
T1b 8 (19) 6 (22) 2 (20) 0 —
T2a 2 (5) 0 2 (20) 0 —
T2b 2 (5) 1 (4) 1 (10) 0 —
T3a 8 (19) 8 (30) 0 0 —
T3b 3 (6) 3 (11) 0 0 —
T3c 0 0 0 0 —
T4 0 0 0 0 —
Fuhrman grade
1 4 (12) 3 (11) — 1 (17) —
2 21 (64) 17 (63) — 4 (66) —
3 6 (18) 5 (19) — 1 (17) —
4 2 (6) 2 (7) — 0 —
MVD
Lesion 439.20 (105–1230) 488.66 (238–1230) 412 (105–769) 256 (108–482) 444.3 (288–492)
Parenchyma 266.97 (71–537) 222.29 (80–238) 506.3 (80–537) 240.16 (71–458) 262.6 (162–322)
Perfusion1 CT study type
Cine 13 (26) 8 (30) 1 (10) 2 (34) 2 (34)
Shuttle 36 (74) 19 (70) 9 (90) 4 (66) 4 (66)
Multiphase CT study type
B-CM-NG-E 40 (82) 22 (81) 8 (80) 4 (66) 6 (100)
B-CM-NG 9 (18) 5 (19) 2 (20) 2 (34) 0
CT characteristics
Hypervascular 25 (51) 17 (63) 2 (20) 2 (34) 4 (66)
H with necrosis 14 (29) 10 (37) 2 (20) 0 2 (34)
Hypovascular 10 (20) 0 6 (60) 4 (40) 0
There were 49 lesions in 41 patients; ∗one patient had two different histologic types of lesions: one clear cell RCC and one papillary RCC. Oncocytomas were
not staged because the staging criteria only applied to RCCs. RCC: renal cell carcinoma;𝑁: number; UP: upper pole; MR: mesorenal region; LP: lower pole;
MVD: microvascular density; B: baseline phase; CM: corticomedullary phase; NG: nephrographic phase; E: excretory phase; H: hypervascular.
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Table 2: Comparison among the CTp parameters: lesions versus normal cortex.
CTp parameters MLs NRC P value Oncocytomas NRC P value
PS 14.21 38.47 <0.001 35.98 37.74 0.6002
MTT 6.73 4.19 0.011 2.57 2.72 0.7532
BV 15.57 17.08 0.29 18.90 15.02 0.7532
BF 302.87 351.72 0.17 477.02 434.21 0.3454
MLs: malignant lesions; NRC: normal renal cortex; PS: permeability surface; MTT: mean transit time; BV: blood volume; BF: blood flow; a 𝑃 value less than
0.05 indicated a statistically significant difference.
(a) (b)
(c) (d)
Figure 2: CTp of oncocytoma: ROI 1, ROI 2, and ROI 3 were drawn in the aorta, tumour, and healthy ipsilateral renal cortex, respectively
(a-b). The PS values of the tumour and normal cortex were 56.39mL/100 g/min and 57.28mL/100 g/min, respectively, whereas MTT values
were 10.48 sec and 9.65 sec, respectively (b). Lesion size was 20mm. Histopathology: morphology, haematoxylin, and eosin (c) and CD34
stain (d); original magnification: 50x.
Table 3: Comparison among the CTp parameters: malignant lesions versus oncocytomas.
CTp parameters Oncocytomas All MLs P value Oncocytomas MHLs P value
PS 35.98 14.21 <0.001 35.98 13.91 0.009
MTT 2.57 6.73 0.0109 2.57 6.08 0.0279
BV 18.90 15.57 0.2111 18.90 17.10 0.4596
BF 477.02 302.87 0.0240 477.02 344.55 0.0868
MLs: malignant lesions; MHLs: malignant hypervascular lesions; PS: permeability surface; MTT: mean transit time; BV: blood volume; BF: blood flow; a 𝑃
value less than 0.05 indicated a statistically significant difference.
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Figure 3: Box whiskers graphics: permeability surface values in different histological type of renal lesions (a); difference of permeability
surface values between lesion and normal cortex in different histological type of renal lesions (b). The boxes display the interquartile range
(the 25th and 75th percentile) and the median of CTp measurements for the four histologic subtypes. The whiskers display the upper and
lower values within 1.5 times the interquartile range beyond the 25th and 75th percentile. Any outliers beyond those limits get their own
markers (dot mark).
93.88%). The difference between the normal cortex and
tumoural PS values yielded an evenmore accurate result; with
2.5mL/100 g/min as a cutoff we achieved a sensitivity, speci-
ficity, and accuracy of 100%, 66.67%, and 95.92%, respectively,
to predict RCCs. The results of the ROC analysis regarding
the comparison between oncocytomas and all malignant
lesions PS and between oncocytomas and malignant hyper-
vascular lesions PS are illustrated in Table 4. The box and
whisker plots regarding the absolute PS and the difference
between normal cortex and tumoural PS values of different
histologic types of tumour are presented in Figure 3.
3.2. Attenuation Measurements. Graphs and data depicting
enhancement patterns are demonstrated in Figure 4. Signif-
icant differences between oncocytomas and malignant renal
lesions were noted in absolute (𝑃 = 0.0087) and percentage
(𝑃 = 0.0061) enhancement in the CM phase. Significant
differences in absolute (𝑃 = 0.0265) and percentage (𝑃 =
0.0158) enhancement in CM phase were also noted, among
hypervascular lesions and in particular among oncocytomas
and malignant lesions. The multiphasic CT measure with the
greatest accuracy for discriminating benign from malignant
lesions was an absolute enhancement in CM phase. Using
ROC analysis, the optimal cutoff value in this study was ≤160
HU enabling a sensitivity, specificity, and accuracy rate of
95.3%, 50%, and 89.8%, respectively, to predict RCCs.
3.3. MVD Analysis. The CTp parameters BF and BV mea-
sured in the tumour cross-section ROI showed a positive
correlation with tumour cross-section MVD in malignant
lesions (𝑃 = 0.006 and 𝑃 = 0.0026, resp.) but not in oncocy-
tomas. No significant correlations were found between other
CTp or multiphasic parameters (absolute enhancement in
CM, NG, or excretory phase) and the tumour cross-section
MVD.
Table 4: ROC analysis.
(a) ROC analysis using difference between normal cortex and tumoural PS
values
Oncocytomas versus
MHLs
Oncocytomas versus
all MLs
Area under ROC
curve 0.85 (C.I. 0.59–1) 0.85 (C.I. 0.60–1)
Threshold value(s) NC PS-tumour PS
>2.5
NC PS-tumour PS
>2.5
Sensitivity 100% 100%
Specificity 66.67% 66.67%
Accuracy 94.87% 95.92%
(b) ROC analysis using absolute enhancement in corticomedullary phase
Oncocytomas versus
MHLs
Oncocytomas versus
all MLs
Area under ROC
curve 0.79 (C.I. 0.61–0.96) 0.83 (C.I. 0.69–0.97)
Threshold value(s) <160 <160
Sensitivity 93.94% 95.35%
Specificity 50% 50%
Accuracy 87.18% 89.80%
Results of ROC curve analysis in predicting RCCs in relation to onco-
cytomas using difference in PS values and absolute enhancement in
corticomedullary phase. PS: permeability surface; MHLs: malignant hyper-
vascular lesions;MLs:malignant lesions; NCPS: normal cortex permeability
surface.
4. Discussion
RCC represents a different spectrum of disease with different
features and clinical behaviours, largely depending on the
histologic type. The most aggressive type is clear cell RCC
whereas papillary RCC and chromophobe RCC can both
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Figure 4: Patterns of enhancement on multiphasic imaging of 49
renal masses by tumour histology.
be considered indolent, because of their low metastatic
potential. However differential diagnosis of renal masses also
includes benign lesions (about 20%) and oncocytoma is the
most common type [2, 3]. Over the last few years, the intro-
duction of nephron-sparing nephrectomy has changed the
approach to early stage renal cancer, allowing reduced com-
plication rates with survival rates similar to total nephrec-
tomy. In this sense, renal lesions characterisation should be
mandatory in order to recognise a small RCC which could
be treated through a partial nephrectomy rather than a wait
and see approach. Moreover, differentiating benign lesions
is important in order to avoid unnecessary surgery. Despite
the widespread use of multimodality imaging, the charac-
terisation of renal lesion still remains poor in some cases,
particularly those of small size (<40mm) [4–6]. In fact, while
papillary RCC typically shows low contrast-enhancement at
CT, oncocytoma and clear cell RCCs can have similar features
and postcontrastographic behaviour, making a differential
diagnosis difficult when it should be mandatory [7, 15, 16].
Several studies, using multiphase CT technique, identified
differing degrees of enhancement in different postcontrast
phases as the most reliable parameter to distinguish clear cell
RCCs from other subtypes, including oncocytomas [16–18].
According to these studies, we also report differing degrees
of contrast-enhancement between clear cell RCCs and other
subtypes, including oncocytomas; however in contrast with
them, in our study, as in the study of Gakis et al., oncocytoma
presented a wash-in similar to renal cortex and clear cell
RCCs had a lower enhancement than oncocytomas during
any given phase, whereas they described a higher contrast-
enhancement as a distinctive feature for discriminating clear
cell RCCs in relation to oncocytomas [18–20]. Moreover, in
our study, as previously reported by others, we identified
that both clear cell RCCs and oncocytomas could show
two different morphological features, being homogeneously
hypervascular (17 and 4 cases, resp.) and hypervascular with
a necrotic core (10 and 2 cases, resp.); in a few cases, even
chromophobe RCCs and papillary RCCs had the same CT
appearances [7, 16]. For this reason, we tested both multipha-
sic CT and CTp in discriminating malignant lesions in this
subgroup. Furthermore still in this subgroup (hypervascular
lesions), absolute percentage enhancement in CM phase was
significantly higher in oncocytomas than inmalignant lesions
(𝑃 = 0.02 and 𝑃 = 0.01, resp.), and ROC analysis showed
an accuracy rate of 94% using <160HU in absolute enhance-
ment as a cutoff for identification of malignant lesions. No
significant differences in lesion-cortex ratio or in lesion-
aorta ratio were identified in any given phase. To the best of
our knowledge, this is the first study which has compared
the same series of lesions by using both multiphasic CT
and CTp. CTp allows the quantitative evaluation of a tissue
perfusion whilst also optimising the acquisition protocol
and has shown promising results in the oncologic field,
even in RCC characterisation [10, 21, 22]. Like the recent
studies, we found significant differences in PS and MTT
values between malignant lesions (clear cell RCCs, papillary
RCCs, and chromophobe RCCs) and the normal renal cortex
(𝑃 < 0.001 and 𝑃 = 0.029, resp.); however in our study BF
and BV values were not significant; moreover, none of the
CTp parameters evaluated in oncocytomas demonstrated
significant differences from those of a normal renal cortex
[10, 23, 24]. We also report significant lower values, in PS,
MTT, andBF values (𝑃 < 0.001,𝑃 = 0.01, and𝑃 = 0.02, resp.)
in malignant lesions in comparison with oncocytomas, and
these results were confirmed for PS and MTT values con-
sidering only the hypervascular subgroups (those with a
necrotic core versus those homogeneously hypervascular).
These results could be explained by alterations of microvessel
architecture in RCC, whereas oncocytomas, instead, appear
to exhibit normal architecture, very close to the normal
renal cortex. In fact, by evaluating a possible correlation of
perfusion parameters with histological findings, particularly
with microvessel density (MVD), a prognostic marker of
RCC, we found a significant correlation between BF and BV
and MVD (𝑃 < 0.01), suggesting that these CTp parameters
may reflect blood vessels and then neoangiogenesis of RCCs,
as also suggested by previous studies [10, 24]. At ROC curve
analysis, the difference between normal cortex and tumoural
PS values yielded the best result with a cutoff greater than
2.5mL/100 g/min with a sensitivity, specificity, and accuracy
of 100%, 66.67%, and 95.92%, respectively, to predict RCCs.
No increased accuracy rate was obtained by considering both
multiphase CT and CTp analysis. Previous studies tried to
describe and differentiate the renal lesions according to the
morphological criteria alone, which is often possible in large
lesions, but which can be difficult for small lesions, or accord-
ing to different multiphasic enhancement patterns upon CT
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examination, or using CTp parameters alone [10, 16–20]. One
of the unique elements of our study is that it is the first which
considers two different CT techniques in the evaluation of the
same series of renal tumours; however it has some limitations.
Firstly, the number of renal lesions is low (49 lesions), and
the subgroup of benign lesions included is relatively small
(6 lesions, 12%). This could explain the low sensitivity and
specificity rates obtained byROCanalysis in bothmultiphasic
CT andCTp analyses, respectively. Increasing the case history
could strengthen the results. Furthermore some common
renal lesions, like angiomyolipoma with minimal fat, are
not represented in our case population. Secondly, only 49%
of the lesions are small renal lesions (<40mm), which are
those with uncertain management: some authors, in fact,
claimed that a followup with an active surveillance instead
of surgical excision should be considered in these cases, in
particular if old age, decreased life expectancy, or extensive
comorbidities are associated [25]. Furthermore papillary
RCCs are significantly smaller than other tumours and this
could influence the vascularisation patterns, even if several
studies reported similar enhancement patterns for both small
and large papillary RCCs [26]. Finally the CTp showed
some limitations. Patients compliance is needed; in our
experience 8 patients were excluded because of respiratory
artifacts; moreover, it is not standardised yet, depending on
several factors including the hardware platform and software
algorithm [11, 27].
5. Conclusion
This study, even with the limitations just considered, showed
the feasibility of CTp in discriminating between renal cell
carcinoma and oncocytoma, which can be an aid in manage-
ment of renal lesions. In particular we would like to state not
only a standard cutoff for CTp analysis, but also a significant
difference between renal cortex and tumour CTp parameter
values that may suggest a malignant lesion. In an era with
increased interest in active surveillance, future studies will
determine whether adding CTp measurements could further
refine our predictive ability in the characterisation of renal
masses.
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